BioSante Pharmaceuticals to Discuss LibiGel(R) SPA in the Treatment of FSD, at BIO CEO and Investor Conference.LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BPAX) today announced that Stephen M. Simes, its president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. will discuss BioSante's recently granted special protocol assessment (SPA) for the Phase III development of LibiGel (testosterone gel) in the treatment of female sexual dysfunction sexual dysfunction Inability to experience arousal or achieve sexual satisfaction under ordinary circumstances, as a result of psychological or physiological problems. (FSD FSD Female Sexual Dysfunction FSD File System Driver FSD Family Support Division FSD Fire Services Department (Hong Kong) FSD Full Scale Development FSD Full Scale Deflection FSD Federal Systems Division ), at the BIO CEO and Investor Conference at the Waldorf Astoria in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Mr. Simes will present on February 11, 2008 at 2:45 p.m. local time. A corporate update and overview also will be presented. The BIO conference provides a forum for institutional investors, industry analysts, and senior biotechnology executives to have the opportunity to shape the future investment landscape of the biotechnology industry. A live audio webcast of BioSante's presentation at the BIO conference may be accessed at http://www.biosantepharma.com/Webcasts.php and a replay will be available at the same link for 90 days. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante's lead products include LibiGel([R]) (transdermal testosterone gel) in Phase III clinical development by BioSante under an FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. SPA for the treatment of female sexual dysfunction (FSD) and Elestrin[TM] (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor vasomotor /vaso·mo·tor/ (-mo´tor) 1. affecting the caliber of blood vessels. 2. a vasomotor agent or nerve. va·so·mo·tor adj. symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee. Also in development are Bio-T-Gel[TM], a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine (BioLook[TM]). Additional information is available online at: www.biosantepharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion